NUTRINEAL PD4 DIN 02230810
Health Canada record
| Active ingredient(s) | VALINE 139.3 MG; LEUCINE 102 MG; ISOLEUCINE 85 MG; DL-METHIONINE 85 MG; LYSINE (LYSINE MONOHYDROCHLORIDE) 95.5 MG; HISTIDINE 71.4 MG; THREONINE 64.6 MG; PHENYLALANINE 57 MG; TRYPTOPHAN 27 MG; ARGININE 107.1 MG; ALANINE 95.1 MG; PROLINE 59.5 MG; GLYCINE 51 MG; SERINE 51 MG; TYROSINE 30 MG; SODIUM CHLORIDE 538 MG; SODIUM LACTATE 448 MG; CALCIUM CHLORIDE 18.4 MG; MAGNESIUM CHLORIDE 5.1 MG |
|---|---|
| Dosage form | Liquid |
| Route | Haemodialysis |
| Schedule | ETHICAL |
| Class | Human |
| ATC | B05ZA HEMODIALYTICS, CONCENTRATES |
| Original market date | 25-Sep-1998 |
| Current status date | 02-Nov-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Baxter Corporation — licence 100278, currently licensed, last inspection rating C (2026-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VALINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02141450 | 20% PROSOL | BAXTER CORPORATION | Liquid | VALINE 1.44 G; LYSINE (LYSINE ACETATE) 1.35 G; HISTIDINE 1.18 G; ISOLEUCINE 1.08 G; LEUCINE 1.08 G; PHENYLALANINE 1 G; THREONINE 0.98 G; DL-METHIONINE 0.76 G; TRYPTOPHAN 0.32 G; ALANINE 2.76 G; GLYCINE 2.06 G; ARGININE 1.96 G; PROLINE 1.34 G; GLUTAMIC ACID 1.02 G; SERINE 1.02 G; L-ASPARTIC ACID 0.6 G; TYROSINE 0.05 G | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 3275 | 1997-02-27 | New Drug Submission (NDS) |
International API supply for VALINE
7 valid EDQM Certificates of Suitability from 7 holders. 5 active FDA Drug Master Files.
Request a quote for NUTRINEAL PD4